vs
CorMedix Inc.（CRMD）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
CorMedix Inc.的季度营收约是RE/MAX Holdings, Inc.的1.8倍（$128.6M vs $71.1M），CorMedix Inc.自由现金流更多（$92.7M vs $33.5M）
CorMedix Inc.是一家处于商业阶段的生物制药企业，专注于开发及商业化用于预防和治疗感染性、炎症性及心肾疾病的创新治疗产品，核心管线针对导管相关血流感染，主要服务北美、欧洲的重症监护及长期透析患者群体。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
CRMD vs RMAX — 直观对比
营收规模更大
CRMD
是对方的1.8倍
$71.1M
自由现金流更多
CRMD
多$59.2M
$33.5M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $128.6M | $71.1M |
| 净利润 | — | $1.4M |
| 毛利率 | 83.4% | — |
| 营业利润率 | 46.0% | 13.1% |
| 净利率 | — | 2.0% |
| 营收同比 | — | -1.8% |
| 净利润同比 | — | -75.2% |
| 每股收益（稀释后） | $0.20 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRMDRMAX
| Q4 25 | $128.6M | $71.1M | ||
| Q3 25 | $104.3M | $73.2M | ||
| Q2 25 | $39.7M | $72.8M | ||
| Q1 25 | $39.1M | $74.5M | ||
| Q4 24 | — | $72.5M | ||
| Q3 24 | — | $78.5M | ||
| Q2 24 | — | $78.5M | ||
| Q1 24 | — | $78.3M |
净利润CRMDRMAX
| Q4 25 | — | $1.4M | ||
| Q3 25 | $108.6M | $4.0M | ||
| Q2 25 | $19.8M | $4.7M | ||
| Q1 25 | $20.6M | $-2.0M | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | — | $966.0K | ||
| Q2 24 | — | $3.7M | ||
| Q1 24 | — | $-3.4M |
毛利率CRMDRMAX
| Q4 25 | 83.4% | — | ||
| Q3 25 | 89.3% | — | ||
| Q2 25 | 95.3% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率CRMDRMAX
| Q4 25 | 46.0% | 13.1% | ||
| Q3 25 | 49.2% | 25.0% | ||
| Q2 25 | 49.2% | 19.3% | ||
| Q1 25 | 51.5% | 7.2% | ||
| Q4 24 | — | 5.9% | ||
| Q3 24 | — | 19.4% | ||
| Q2 24 | — | 20.6% | ||
| Q1 24 | — | 5.8% |
净利率CRMDRMAX
| Q4 25 | — | 2.0% | ||
| Q3 25 | 104.1% | 5.4% | ||
| Q2 25 | 49.9% | 6.4% | ||
| Q1 25 | 52.8% | -2.6% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 4.7% | ||
| Q1 24 | — | -4.3% |
每股收益（稀释后）CRMDRMAX
| Q4 25 | $0.20 | — | ||
| Q3 25 | $1.26 | — | ||
| Q2 25 | $0.28 | — | ||
| Q1 25 | $0.30 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $148.5M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $405.3M | $452.4M |
| 总资产 | $826.1M | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资CRMDRMAX
| Q4 25 | $148.5M | $118.7M | ||
| Q3 25 | $55.7M | $107.5M | ||
| Q2 25 | $190.7M | $94.3M | ||
| Q1 25 | $77.5M | $89.1M | ||
| Q4 24 | — | $96.6M | ||
| Q3 24 | — | $83.8M | ||
| Q2 24 | — | $66.1M | ||
| Q1 24 | — | $82.1M |
总债务CRMDRMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益CRMDRMAX
| Q4 25 | $405.3M | $452.4M | ||
| Q3 25 | $374.1M | $448.1M | ||
| Q2 25 | $220.6M | $442.4M | ||
| Q1 25 | $114.9M | $433.5M | ||
| Q4 24 | — | $429.5M | ||
| Q3 24 | — | $423.1M | ||
| Q2 24 | — | $418.4M | ||
| Q1 24 | — | $412.0M |
总资产CRMDRMAX
| Q4 25 | $826.1M | $582.5M | ||
| Q3 25 | $750.9M | $582.2M | ||
| Q2 25 | $252.6M | $574.8M | ||
| Q1 25 | $149.6M | $571.4M | ||
| Q4 24 | — | $581.6M | ||
| Q3 24 | — | $578.6M | ||
| Q2 24 | — | $571.4M | ||
| Q1 24 | — | $566.7M |
负债/权益比CRMDRMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $94.5M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $92.7M | $33.5M |
| 自由现金流率自由现金流/营收 | 72.1% | 47.1% |
| 资本支出强度资本支出/营收 | 1.3% | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | $172.8M | $56.8M |
8季度趋势，按日历期对齐
经营现金流CRMDRMAX
| Q4 25 | $94.5M | $40.9M | ||
| Q3 25 | $30.9M | $17.7M | ||
| Q2 25 | $30.0M | $4.6M | ||
| Q1 25 | $19.7M | $5.7M | ||
| Q4 24 | — | $59.7M | ||
| Q3 24 | — | $17.6M | ||
| Q2 24 | — | $15.9M | ||
| Q1 24 | — | $9.4M |
自由现金流CRMDRMAX
| Q4 25 | $92.7M | $33.5M | ||
| Q3 25 | $30.4M | $16.4M | ||
| Q2 25 | $30.0M | $2.9M | ||
| Q1 25 | $19.7M | $4.0M | ||
| Q4 24 | — | $53.0M | ||
| Q3 24 | — | $16.3M | ||
| Q2 24 | — | $14.0M | ||
| Q1 24 | — | $6.8M |
自由现金流率CRMDRMAX
| Q4 25 | 72.1% | 47.1% | ||
| Q3 25 | 29.1% | 22.4% | ||
| Q2 25 | 75.4% | 4.0% | ||
| Q1 25 | 50.5% | 5.3% | ||
| Q4 24 | — | 73.2% | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 17.8% | ||
| Q1 24 | — | 8.6% |
资本支出强度CRMDRMAX
| Q4 25 | 1.3% | 10.4% | ||
| Q3 25 | 0.5% | 1.8% | ||
| Q2 25 | 0.1% | 2.2% | ||
| Q1 25 | 0.0% | 2.3% | ||
| Q4 24 | — | 9.1% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 3.3% |
现金转化率CRMDRMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | 0.28× | 4.45× | ||
| Q2 25 | 1.51× | 0.97× | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRMD
| Acquisition Of Melinta | $52.9M | 41% |
| Melinta Portfolio | $45.5M | 35% |
| Other | $18.6M | 14% |
| Contract Revenue | $7.4M | 6% |
| BARDA Agreement | $4.2M | 3% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
